Daniel Lesueur Sells 5,209 Shares of Health Catalyst, Inc. (NASDAQ:HCAT) Stock

Health Catalyst, Inc. (NASDAQ:HCAT) COO Daniel Lesueur sold 5,209 shares of the business’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $7.51, for a total transaction of $39,119.59. Following the transaction, the chief operating officer now directly owns 91,253 shares of the company’s stock, valued at approximately $685,310.03. This trade represents a 5.40 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Daniel Lesueur also recently made the following trade(s):

• On Tuesday, November 5th, Daniel Lesueur sold 5,209 shares of Health Catalyst stock. The shares were sold at an average price of $7.70, for a total transaction of $40,109.30.

Health Catalyst Price Performance

Shares of NASDAQ HCAT traded down $0.47 during mid-day trading on Friday, reaching $6.89. The company had a trading volume of 477,428 shares, compared to its average volume of 533,036. Health Catalyst, Inc. has a 1-year low of $5.42 and a 1-year high of $11.41. The stock has a market cap of $419.24 million, a PE ratio of -5.10 and a beta of 1.36. The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of 0.32. The company has a 50-day moving average price of $7.81 and a two-hundred day moving average price of $7.52.

Health Catalyst (NASDAQ:HCAT) last posted its quarterly earnings data on Wednesday, November 6th. The company reported $0.07 EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). Health Catalyst had a negative net margin of 26.20% and a negative return on equity of 7.51%. The firm had revenue of $76.40 million for the quarter, compared to analysts’ expectations of $76.27 million. During the same period in the prior year, the company posted ($0.22) earnings per share. Health Catalyst’s quarterly revenue was up 3.5% compared to the same quarter last year. On average, equities analysts anticipate that Health Catalyst, Inc. will post -0.33 earnings per share for the current year.

Hedge Funds Weigh In On Health Catalyst

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Primecap Management Co. CA raised its position in Health Catalyst by 14.7% during the second quarter. Primecap Management Co. CA now owns 2,379,462 shares of the company’s stock valued at $15,205,000 after buying an additional 305,079 shares during the period. Janney Montgomery Scott LLC purchased a new stake in Health Catalyst in the 3rd quarter worth approximately $897,000. Fred Alger Management LLC acquired a new stake in shares of Health Catalyst during the 3rd quarter valued at $6,858,000. Millrace Asset Group Inc. purchased a new position in shares of Health Catalyst during the 3rd quarter valued at $1,568,000. Finally, Point72 Asset Management L.P. raised its holdings in shares of Health Catalyst by 69.4% during the third quarter. Point72 Asset Management L.P. now owns 516,934 shares of the company’s stock worth $4,208,000 after acquiring an additional 211,805 shares in the last quarter. Institutional investors and hedge funds own 85.00% of the company’s stock.

Analysts Set New Price Targets

HCAT has been the topic of several analyst reports. Piper Sandler restated an “overweight” rating and issued a $12.00 price target (up previously from $11.00) on shares of Health Catalyst in a research note on Tuesday, November 26th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $16.00 price objective on shares of Health Catalyst in a report on Friday, October 4th. Stephens boosted their target price on Health Catalyst from $7.00 to $9.00 and gave the stock an “equal weight” rating in a report on Thursday, November 14th. Evercore ISI increased their price target on Health Catalyst from $8.00 to $10.00 and gave the company an “outperform” rating in a research note on Tuesday, October 8th. Finally, Royal Bank of Canada lifted their price target on Health Catalyst from $8.00 to $9.00 and gave the company a “sector perform” rating in a research report on Thursday, November 7th. Two equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, Health Catalyst currently has an average rating of “Moderate Buy” and a consensus target price of $11.45.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.